Robert Driscoll
Stock Analyst at Wedbush
(1.26)
# 3,397
Out of 4,842 analysts
160
Total ratings
28.37%
Success rate
-10.48%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZNTL Zentalis Pharmaceuticals | Reiterates: Neutral | $4 | $1.25 | +221.29% | 11 | May 15, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Outperform | $8 → $6 | $1.28 | +368.75% | 3 | May 9, 2025 | |
| RVMD Revolution Medicines | Reiterates: Outperform | $67 | $39.09 | +71.42% | 5 | Apr 28, 2025 | |
| GLUE Monte Rosa Therapeutics | Maintains: Outperform | $15 → $17 | $4.23 | +302.37% | 4 | Mar 21, 2025 | |
| ARVN Arvinas | Downgrades: Neutral | $57 → $12 | $7.50 | +60.00% | 9 | Mar 12, 2025 | |
| DAWN Day One Biopharmaceuticals | Reiterates: Outperform | $32 | $6.48 | +394.21% | 6 | Feb 26, 2025 | |
| KURA Kura Oncology | Maintains: Outperform | $34 → $36 | $5.81 | +519.62% | 8 | Feb 6, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $52 | $20.04 | +159.48% | 9 | Dec 17, 2024 | |
| TYRA Tyra Biosciences | Reiterates: Outperform | $28 | $9.26 | +202.38% | 8 | Oct 25, 2024 | |
| BDTX Black Diamond Therapeutics | Reiterates: Outperform | $16 | $2.25 | +611.11% | 10 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $9.51 | +215.46% | 7 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $22 | $1.33 | +1,554.14% | 10 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $51 | $7.62 | +569.29% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.72 | +594.44% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $36 | $8.69 | +314.27% | 4 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $1.79 | +514.53% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $4.36 | +198.17% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $2.33 | +457.94% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $24.04 | +207.82% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $2.12 | +277.36% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $1.48 | +372.97% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $8 | $2.52 | +217.46% | 9 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $0.31 | +2,513.52% | 7 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $52 | $9.40 | +453.49% | 5 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $4 | $3.44 | +16.45% | 4 | May 19, 2020 |
Zentalis Pharmaceuticals
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $1.25
Upside: +221.29%
Werewolf Therapeutics
May 9, 2025
Maintains: Outperform
Price Target: $8 → $6
Current: $1.28
Upside: +368.75%
Revolution Medicines
Apr 28, 2025
Reiterates: Outperform
Price Target: $67
Current: $39.09
Upside: +71.42%
Monte Rosa Therapeutics
Mar 21, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $4.23
Upside: +302.37%
Arvinas
Mar 12, 2025
Downgrades: Neutral
Price Target: $57 → $12
Current: $7.50
Upside: +60.00%
Day One Biopharmaceuticals
Feb 26, 2025
Reiterates: Outperform
Price Target: $32
Current: $6.48
Upside: +394.21%
Kura Oncology
Feb 6, 2025
Maintains: Outperform
Price Target: $34 → $36
Current: $5.81
Upside: +519.62%
IDEAYA Biosciences
Dec 17, 2024
Reiterates: Outperform
Price Target: $52
Current: $20.04
Upside: +159.48%
Tyra Biosciences
Oct 25, 2024
Reiterates: Outperform
Price Target: $28
Current: $9.26
Upside: +202.38%
Black Diamond Therapeutics
Oct 8, 2024
Reiterates: Outperform
Price Target: $16
Current: $2.25
Upside: +611.11%
Oct 3, 2024
Reiterates: Outperform
Price Target: $30
Current: $9.51
Upside: +215.46%
Oct 1, 2024
Maintains: Outperform
Price Target: $25 → $22
Current: $1.33
Upside: +1,554.14%
Sep 20, 2024
Maintains: Outperform
Price Target: $85 → $51
Current: $7.62
Upside: +569.29%
Sep 20, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.72
Upside: +594.44%
Sep 18, 2024
Reiterates: Outperform
Price Target: $36
Current: $8.69
Upside: +314.27%
Aug 13, 2024
Reiterates: Outperform
Price Target: $11
Current: $1.79
Upside: +514.53%
Aug 9, 2024
Reiterates: Outperform
Price Target: $13
Current: $4.36
Upside: +198.17%
Aug 8, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $2.33
Upside: +457.94%
Aug 8, 2024
Reiterates: Outperform
Price Target: $74
Current: $24.04
Upside: +207.82%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $2.12
Upside: +277.36%
Jun 7, 2024
Reiterates: Outperform
Price Target: $7
Current: $1.48
Upside: +372.97%
May 9, 2024
Upgrades: Outperform
Price Target: $3 → $8
Current: $2.52
Upside: +217.46%
May 3, 2024
Reiterates: Outperform
Price Target: $8
Current: $0.31
Upside: +2,513.52%
Nov 8, 2023
Reiterates: Outperform
Price Target: $52
Current: $9.40
Upside: +453.49%
May 19, 2020
Upgrades: Outperform
Price Target: $2 → $4
Current: $3.44
Upside: +16.45%